REGENERON PHARMACEUTICALS (REGN) Stock Analyst Ratings
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 81% to REGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 750.26. This target is 47.19% above the current price.
REGN was analyzed by 34 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about REGN.
In the previous month the buy percentage consensus was at a similar level.
REGN was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-06-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-05 | UBS | Maintains | Neutral -> Neutral |
| 2025-06-02 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-06-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-02 | Citigroup | Maintains | Buy -> Buy |
| 2025-05-30 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-05-27 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-14 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-05-01 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-30 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-04-30 | UBS | Maintains | Neutral -> Neutral |
| 2025-04-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-30 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-30 | Baird | Maintains | Neutral -> Neutral |
| 2025-04-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-25 | Baird | Maintains | Neutral -> Neutral |
| 2025-04-23 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-22 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-04-17 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-04-17 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-04-14 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-05 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-02-05 | Baird | Maintains | Neutral -> Neutral |
| 2025-01-28 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-01-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-01-16 | UBS | Downgrade | Buy -> Neutral |
| 2025-01-14 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-01-10 | Wells Fargo | Maintains | Overweight -> Overweight |